Eli Lilly and Company (LLY) key performance indicators and operating metrics (34 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Key Products Revenue | 13.4B | FY2026-Q1 |
| China Revenue | 693M | FY2026-Q1 |
| Rest of World Revenue | 2.77B | FY2026-Q1 |
| Total operating expense | 7.03B | FY2026-Q1 |
| Effective tax rate | 16.50 percent | FY2026-Q1 |
| Jaypirca sales | 165M | FY2026-Q1 |
| Performance margin | 50.00 percent | FY2026-Q1 |
| Ebglyss sales | 145M | FY2026-Q1 |
| Kisunla sales | 124M | FY2026-Q1 |
| Europe Revenue | 3.65B | FY2026-Q1 |
| Japan Revenue | 571M | FY2026-Q1 |
| Verzenio revenue | 1.6B | FY2025-Q4 |
| Revenue outside the United States | 6.4B | FY2025-Q4 |
| Revenue in the United States | 12.9B | FY2025-Q4 |
Back to LLY overview · LLY earnings · LLY holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.